INOVOTION’s CEO, Jean Viallet, was honored to speak at the recent AFFSSI Connexions (https://www.afssi.fr/), during a session focused on the evolving role of New Alternative Methods (NAMs) and the continued importance of in vivo models in drug development. The meeting was held July 1st in Toulouse, France. This was a brilliant session, with other noted speakers including Hugues Contamin (CEO @CYNBIOSE), Émeline Gougeon (Comité Scientifique Pro Anima), Pierre Mormede (CNREEA president), Athanassia Sotiropoulos (Director GIS FC3R).

This opening session, titled “Emerging Alternative Methods and the Role of In Vivo Models in Drug Development,” highlighted how innovation in preclinical research is transforming the field, while reaffirming the critical role of scientifically and ethically optimized in vivo models.
Jean Viallet presented INOVOTION’s pioneering CAM-based NAM platform, which combines the advantages of high biological relevance, rapid turnaround, and reduced animal use. He shared insights into how our model:

–       Provides a predictive and rapid in vivo platform that bridges the gap between in vitro assays and traditional animal studies
–       Supports the 3Rs principles by significantly reducing animal use while maintaining physiological relevance
–       Offers a complementary approach that is scientifically rigorous and is easily integrated into early-stage drug evaluation

As the push for ethical, efficient, and effective preclinical tools grows, INOVOTION is proud to contribute with a solution that meets both innovation and responsibility standards.

Learn more about our platform: https://www.inovotion.com